A microRNA expression signature in taxaneanthracycline-based neoadjuvant chemotherapy response

Journal of Cancer

Volumn 6, Issue 7, 2015, Pages 671-677

  Zheng, Yi ^a,b,c   Li, Shuai ^a,b,c   Boohaker, Rebecca J ^e   Liu, Xinli ^a,b,c   Zhu, Yufen ^a,b,c   Zhai, Lili ^a,b,c   Li, Huilan ^a,b,c   Gu, Feng ^a,b,c   Fan, Yu ^a,b,c   Lang, Ronggang ^a,b,c   Liu, Fangfang ^a,b,c   Qian, Xiaolong ^a,b,c   Xu, Bo ^e   Fu, Li ^a,b,c,d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c State Key Lab of Breast Cancer Research   (China)

^d 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics   (China)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; MicroRNA; Neoadjuvant chemotherapy; Pathologic complete response; Predictive biomarkers

Indexed keywords

ANTHRACYCLINE DERIVATIVE; MICRORNA 125B; MICRORNA 141; TAXANE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL CYCLE REGULATION; CELL SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DRUG RESISTANCE; DRUG RESPONSE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; UPREGULATION;

EID: 84938373367     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11616     Document Type: Article

References (26)

1. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008; 26: 786-790. doi:10.1200/JCO.2008.15.0243.
2. Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012; 30: 1747-1749. doi:10.1200/JCO.2011.41.3161.
3. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30: 1796-1804. doi:10.1200/JCO.2011.38.8595.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
5. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101: 2999-3004. doi:10.1073/pnas.0307323101.
6. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings Of the National Academy Of Sciences Of the United States Of America. 2002; 99: 15524-15529. doi:DOI 10.1073/pnas.242606799.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838. doi:10.1038/nature03702.
8. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009; 137: 1032-1046. doi:10.1016/j.cell.2009.03.047.
9. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 2013; 14: 1295-1306. doi:10.1016/S1470-2045(13)70491-1.
10. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25: 501-515. doi:10.1016/j.ccr.2014.03.007.
11. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010; 141: 1195-1207. doi:10.1016/j.cell.2010.05.017.
12. Boohaker RJ, Xu B. The versatile functions of ATM kinase. Biomed J. 2014; 37: 3-9. doi:10.4103/2319-4170.125655.
13. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20. doi:DOI 10.1016/j.cell.2004.12.035.
14. Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A, et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature. 2009; 459: 1010-1014. doi:10.1038/nature08025.
15. Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle. 2012; 11: 1235-1246. doi:10.4161/cc.11.6.19665.
16. Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013; 73: 6554-6562. doi:10.1158/0008-5472.CAN-13-1841.
17. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010; 285: 21496-21507. doi:10.1074/jbc.M109.083337.
18. Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, et al. miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem. 2013; 288: 4334-4345. doi:10.1074/jbc.M112.419168.
19. Haemmig S, Baumgartner U, Gluck A, Zbinden S, Tschan MP, Kappeler A, et al. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis. 2014; 5: e1279. doi:10.1038/cddis.2014.245.
20. Zhou L, Bai H, Wang C, Wei D, Qin Y, Xu X. microRNA125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. Mol Med Rep. 2014; 9: 1909-1916. doi:10.3892/mmr.2014.2011.
21. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32: 4284-4293. doi:10.1038/onc.2012.433.
22. Zhou X, Su J, Zhu L, Zhang G. Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter. 2014; 19: 174-181. doi:10.1111/hel.12120.
23. Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet. 2011; 56: 270-276. doi:10.1038/jhg.2011.1.
24. Guo X, Yang C, Qian X, Lei T, Li Y, Shen H, et al. Estrogen receptor alpha regulates ATM Expression through miRNAs in breast cancer. Clin Cancer Res. 2013; 19: 4994-5002. doi:10.1158/1078-0432.CCR-12-3700.
25. Sun M, Guo X, Qian X, Wang H, Yang C, Brinkman KL, et al. Activation of the ATM-Snail pathway promotes breast cancer metastasis. J Mol Cell Biol. 2012; 4: 304-315. doi:10.1093/jmcb/mjs048.
26. Boohaker RJ, Cui X, Stackhouse M, Xu B. ATM-mediated Snail Serine 100 phosphorylation regulates cellular radiosensitivity. Radiother Oncol. 2013; 108: 403-408. doi:10.1016/j.radonc.2013.06.017.